Because the prevailing form of hormone replacement therapy is associated with the development ofcancer in breast and endometrial tissues, alternatives are needed for the management of menopausalsymptoms. Formulations of
Trifolium pratense L. (red clover) are being used to alleviate menopause-associated hot flashes but have shown mixed results in clinical trials. The strobiles of
Humulus lupulusL. (hops) have been reported to contain the prenylflavanone, 8-prenylnaringenin (8-PN), as the mostestrogenic constituent, and this was confirmed using an estrogen receptor ligand screening assayutilizing ultrafiltration mass spectrometry. Extracts of hops and red clover and their individualconstituents including 8-PN, 6-prenylnaringenin (6-PN), isoxanthohumol (IX), and xanthohumol (XN)from hops and daidzein, formononetin, biochanin A, and genistein from red clover were comparedusing a variety of in vitro estrogenic assays. The IC
50 values for the estrogen receptor
and
bindingassays were 15 and 27
g/mL, respectively, for hops and 18.0 and 2.0
g/mL, respectively, for thered clover extract. Both of the extracts, genistein, and 8-PN activated the estrogen response element(ERE) in Ishikawa cells while the extracts, biochanin A, genistein, and 8-PN, significantly inducedERE-luciferase expression in MCF-7 cells. Hop and red clover extracts as well as 8-PN up-regulatedprogesterone receptor (PR) mRNA in the Ishikawa cell line. In the MCF-7 cell line, PR mRNA wassignificantly up-regulated by the extracts, biochanin A, genistein, 8-PN, and IX. The two extracts hadEC
50 values of 1.1 and 1.9
g/mL, respectively, in the alkaline phosphatase induction assay. On thebasis of these data, hops and red clover could be attractive for the development as herbal dietarysupplements to alleviate menopause-associated symptoms.Keywords: Alkaline phosphatase; estrogen receptor; hops;
Humulus lupulus; menopause; progesterone receptor; red clover;
Trifolium pratense